SHAHEED RAJAIE CARDIOVASCULAR MEDICAL CENTER, MELLAT PARK, VALI-ASR AVE., TEHRAN, IRAN
Abstract
Objective- This randomized, double blind trial was designed to compare the efficacy and safety of ezetimibe, a new cholesterol-lowering agent with atorvastatin (Lipitor), a potent cholesterol inhibitor derivative. Method- Between September 2004 and March 2005, a total of 120 hyperlipidemic patients, aged 28-80 years, were randomized to receive ezetimibe 10 mg or atorvastatin 10 mg orally daily for 8 weeks after a 4-week washout phase and diet on NCEP step n. Mean changes of serum lipoproteins after 4 and 8 weeks of drug therapy were measured and compared in both groups of patients. Results- Ezetimibe reduced LDLc and total cholesterol by a mean of 27% and 16% compared with 32% and 24% for atorvastatin, respectively. The difference was not statistically significant. Conclusion- Ezetimibe and atorvastatin both reduced LDLc and TC with no statistically significant difference.
MOMTAHEN, M., FARSAD, F., ABAS, M., MOMTAHAN, S., & KAZAZI, A. (2007). DOUBLE BLIND RANDOMIZED CLINICAL TRIAL OF EZETIMIBE VERSUS ATORVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA. Iranian Heart Journal, 8(1), 33-37.
MLA
M. MOMTAHEN; F. FARSAD; M. ABAS; S. MOMTAHAN; A.S.A.D. KAZAZI. "DOUBLE BLIND RANDOMIZED CLINICAL TRIAL OF EZETIMIBE VERSUS ATORVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA". Iranian Heart Journal, 8, 1, 2007, 33-37.
HARVARD
MOMTAHEN, M., FARSAD, F., ABAS, M., MOMTAHAN, S., KAZAZI, A. (2007). 'DOUBLE BLIND RANDOMIZED CLINICAL TRIAL OF EZETIMIBE VERSUS ATORVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA', Iranian Heart Journal, 8(1), pp. 33-37.
VANCOUVER
MOMTAHEN, M., FARSAD, F., ABAS, M., MOMTAHAN, S., KAZAZI, A. DOUBLE BLIND RANDOMIZED CLINICAL TRIAL OF EZETIMIBE VERSUS ATORVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA. Iranian Heart Journal, 2007; 8(1): 33-37.
)